Appealing a GLP-1 coverage denial: an overview of prior authorisation, the label indications that matter, and the appeal rights you have

A denial letter for a GLP-1 is rarely a judgement about you. It is a statement that a form did not match a rule. The rule is usually written down, the form can be resubmitted, and federal law gives you two rounds of appeal. This guide is the overview: how to read the letter, what the labels let a prescriber certify, and how the process runs. The GLP-1 Pricing Index carries the plan-by-plan coverage tables, Medicare and Medicaid status and manufacturer self-pay programs that this page deliberately does not duplicate, and the tools site has the appeal letter template and prior-authorisation checklist.

Read the denial letter for the reason code

Every denial names a reason, sometimes in a code and a sentence. Nearly all fall into four categories.

Plan exclusion. The plan does not cover drugs for weight management at all, as a class. This is a benefit design decision, not a medical one, and it is the hardest to appeal on medical grounds. The route around it is a different label indication that the plan does cover (see below) or the manufacturer self-pay programs on the pricing site.

Indication mismatch. The drug was prescribed for a use the plan does not cover, or the diagnosis code on the claim does not match the label indication the plan requires. Ozempic for weight loss without diabetes is the classic case; so is Wegovy with a diagnosis code that does not include the cardiovascular history the plan needs to apply its cardiovascular criteria.

Prior authorisation criteria not met or not documented. The plan covers the drug but requires evidence that you meet its criteria: a BMI at or above a threshold, a weight-related comorbidity, a documented period of lifestyle intervention, specific lab values. The denial often means the paperwork did not contain the evidence, not that you lack it.

Step therapy. The plan requires a trial of another drug first (commonly an older, cheaper weight-management medication, or for diabetes, metformin) and there is no record of one. Some states restrict step therapy and most plans have an exception process for people who have tried and failed the step drug or for whom it is contraindicated.

Identify which category you are in before writing a word. Appealing an exclusion with a medical necessity letter, or appealing a documentation gap with an argument about fairness, both fail.

What the labels let a prescriber certify

Plan criteria are almost always built from the labels' indication sections, so knowing them tells you what the appeal has to demonstrate.

Wegovy is indicated, per its label, to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight (the indication approved by FDA on March 8, 2024, on the basis of the SELECT trial); for weight reduction and long-term maintenance in adults and adolescents with obesity, or adults with overweight plus at least one weight-related comorbidity; and for noncirrhotic MASH with moderate to advanced fibrosis in adults. The BMI thresholds the label uses for the weight-management indication are 30 kg/m2 or greater, or 27 or greater with a comorbidity.

Zepbound is indicated for weight reduction and long-term maintenance in adults with obesity, or overweight with at least one weight-related comorbidity, on the same BMI thresholds; and for moderate to severe obstructive sleep apnoea in adults with obesity (approved December 20, 2024).

Ozempic and Mounjaro are indicated for type 2 diabetes, with Ozempic carrying additional cardiovascular and kidney indications in that population. A plan that covers them will generally require a diabetes diagnosis, and prescribing them for weight loss without one is off-label, which most plans will not cover.

The practical consequence: a person with obesity and established heart disease has a Wegovy indication that many plans treat differently from the weight-management one, and a person with obesity and diagnosed moderate-to-severe sleep apnoea has a Zepbound indication with the same property. Whether the diagnosis exists, is documented, and appears on the claim is the whole appeal. The prescriber checklist includes the question to ask about which indication is being claimed. None of this is a suggestion to seek a diagnosis you do not have; it is a reason to make sure the ones you do have are on the record.

The medical necessity letter

The letter is written by the prescriber; you can make it better by supplying the material. It should state the diagnosis and the label indication being claimed, with the ICD-10 codes; the BMI and the date it was measured, plus the comorbidities with their own documentation (blood pressure readings, HbA1c, lipid panel, sleep study result); the history of prior attempts at weight management with dates, including any prior medications and why they were stopped, which addresses step therapy; the specific plan criteria, quoted, with a line for each showing how they are met; and the clinical consequence of not treating. It should be short. Reviewers read hundreds.

Do not include testimonials, forum evidence, or general statements about how effective the drug is; the reviewer knows. Do include the label indication by name, because that is what their criteria are keyed to.

The appeal process

HealthCare.gov sets out the two-stage process that applies to most private plans under the Affordable Care Act. First, an internal appeal: you (or your prescriber on your behalf) ask the plan to reconsider, in writing, within the deadline on the denial letter, which is generally 180 days. The plan must review it and respond within set time limits, shorter for urgent cases. Second, if the internal appeal is denied, an external review by an independent third party, whose decision the plan must accept. The denial letter is required to explain how to request each.

Employer self-funded plans follow the federal ERISA claims-procedure rules, which have the same shape: a right to the plan's criteria and the reviewer's rationale on request, a right to internal appeal, and a right to external review for medical judgement denials. Medicare Part D and Medicaid have their own appeal ladders; the pricing site covers them.

Ask for the plan's clinical criteria document for the drug in writing. You are entitled to it, and appealing without it is guesswork.

Timelines and tactics

Appeal fast; do not wait for the deadline. Ask the prescriber's office whether they will file, and whether they use a standard template; most offices have one, and the tools site's template is a starting point if they do not. Keep every document: the denial, the criteria, the letter, the fax confirmation, the call reference numbers. If the drug is already working and a lapse would mean re-escalating from the starting dose (see the dose escalation guide), say so in the appeal and ask for expedited review; continuity of an established treatment is a recognised ground.

If the appeal is about a formulary preference (the plan covers one GLP-1 and not the other), the switching guide covers what a switch involves; sometimes accepting the covered drug is the faster route to treatment.

While the appeal runs

Manufacturer savings cards and self-pay programs, and their eligibility rules, change often; the pricing site's program pages track them with dates. FormBlends' own GLP-1 cost report sets out the cost landscape, and its semaglutide and tirzepatide pages describe the compounded products its pharmacies dispense, which insurance does not cover and which are not FDA approved or interchangeable with the brand products this guide discusses. That is a commercial interest of the site's publisher, disclosed here as everywhere on this network.

When the answer is finally no

An exclusion that survives external review is a benefit-design fact until the plan year changes. Open enrolment is the point at which coverage can change; plans publish formularies in advance and the pricing site tracks which cover which drugs. Employer plans can be lobbied through HR, and the argument that works is a cost one (the cardiovascular and sleep-apnoea indications give it substance), not a personal one.